Member Info for Akhtar234

Wow that is a turnaround

It will be her decision if her strategy is to realign the cash to investing and from what i have read (Have to see what is finally said) then it is solely her strategy and she has already started mooting to big Institutions.

Will be interesting to see what the big guys do as a lot will already know of her plans and shared what they think.

Cant compare Divi All at sea, look at the SP growth.

Astra Share price more than doubled in the last 5 years, 10 Years Quadruppled

GSK is nearly down by c10% in the last 5 years , down 20% last 10

Yes Astra have not increased the dividend but shareholders have gained by the absolute returns. Now would you be happy of c 10% extra income, or 110% Growth last 5 years??

EW has been at GSK for last decade, see what her strategy is, i am in two minds, I dont think she is the right person going forward, but she has been making acquisitions of late and invested in VIR last year, albeit was it cheap or expensive jury is out. If VIR really does transform it would have been a masterstroke for GSK and she has credit as it was made under her watch.

Dont disagree and he made an a**e of himself during the 2008 crash, that Jon Stewart ridiculed him for.

https://www.youtube.com/watch?v=l9tclPuq6TY

Can someone who attends the meeting share what is discussed on here please?

https://www.thetimes.co.uk/article/the-questions-facing-walmsley-as-gsk-break-up-looms-h0wn756xf

Dame Emma Walmsley will today finally update the City on the strategy of GlaxoSmithKline at its eagerly awaited capital markets day.

At stake from the virtual event is the potential future independence of one of Britain’s largest drug groups, as well as the prospect of Walmsley, after four years in charge, continuing to lead “New GSK” beyond a planned break-up of the group.
Sponsored

Investors and analysts will be looking for clarity from a number of key questions at what Bank of America, GSK’s joint-house broker, has called an “important watershed for the company”.

https://www.cnbc.com/2021/06/22/jim-cramer-glaxosmithkline-investor-meeting-could-set-up-buyable-dip.html

CNBC’s Jim Cramer gave investors a primer on what to watch for when pharmaceutical giant GlaxoSmithKline holds an investor day Wednesday morning.

The British-based company currently pays out a 5.56% dividend to shareholders as CEO Emma Walmsley leads a reshuffling in the business.

“If the rumors are true and GlaxoSmithKline really takes a meat-ax to its dividend, then I think you need to be prepared for the stock to get slammed as income-oriented investors dump it,” he said Tuesday on “Mad Money.” “But after it sells off, you could get a good buying opportunity.”

Since she became CEO in April 2017, GlaxoSmithKline shares are down more than 7% at $39.08 as of Tuesday’s close, giving it a $93 billion market cap.

“If that’s really the plan, I think she’s misjudged her shareholder base. There are a lot of people who own big pharma stocks for the income; the last thing they want is a dividend cut,” Cramer said. “The dividend is literally the best thing about the stock — it’s called income.”

Thanks never heard of them, but insurance?

Sorry in reference to Arc, second paragraph

LOl Wisha you insinuated a deal was made in your post.

LOL@Seisnav

Which broker do you buy the bonds through?

It will make money the bits, why i have held. I would have waited and thought you were going to as your looking at charts.

I suspect this will be a good strategy as the have consulted with the big boys and are under pressure. This for me is a solid long term company that needs to be rejuvenated. Have seen on twitter the break up is £50bn for each business so £100bn.

Wisha, what offer ? nothing has been disclosed externally yet, unless I have missed something.

If we dont get a spikey leak in the next 1.5 weeks ahead of the EA agreement end date, either we extend or have rejected an offer behind the scenes. Can not see this going to the wire.

Rothschild will be retained if no deal with AAL, they know they can do well here on any future deal.

Denby I would wait till the Wednesday meeting, to gage what others are thinking.

I think it will be a positive long term, but have to see the strategy.

Drilling is not expensive and depending on them targetting specific areas to hone in, then it can be done, for any AIM listed company shareholders are wary of dilution.

Would be risky if we was solely relying on AAL, but we are not as shorn has said, not long to go and we know what direction we are going in, deal or no deal, for me it is proving we are worth multiples to what we are now and i think the answer is yes.

There is always a push back and it has fallen before, depends what the strategy outlined. If they are ambitious could be further catalyst.

Dont disagree with you, think she is a waste of space, but let her deliver on the strategy and then get rid of her. But dont think it is solely her fault. Previous idiots sold off oncology and didnt invest enough.

If we follow Astra lead, yes divi income will hurt, the growth will outgrow and make up for it.

I dont disagree, in the US, the companies are known to be poor income payers, they have always chased for growth. Was just citing a possible reason why it does not go up. Also if if you look at the dividends, at first it looked like they have no intention of increasing and would be subject to board approvals. But, if you look at slide 13 https://www.bp.com/content/dam/bp/business-sites/en/global/corporate/pdfs/investors/bp-first-quarter-2021-results-presentation-slides-and-script.pdf the dividend cash is flat (Dark green) but if the share buy back (light green) start increasing, then they can increase dividends without increasing the absolute amounts, which is good. That make this more attractive and the increase cost savings will make the business cash richer. To possibly increase investments in renewables aswell as cutting down the debt.

It has lagged to oil, but remember dividends were cut and i feel they are waiting to see how the oil demand pans out. this has been held back, but oil higher than $45 it is a cash generative business.

Yes the share price is the main reason here, but it is not a surprise and had to be cut, due to poor management decisions in the past.

She is out of her depth, but given a chance, but she can not run the pharma business post spin off.

This will be a better company in the mid to long term.